


Pharmaceuticals & Biotechnology | Small Cap
Gufic BioSciences Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation and efficient use of capital. Revenue and asset growth are also positive signs. However, liquidity is a concern, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios are low, which could point to issues with asset utilization. While the company maintains a good dividend coverage, declines in operating profit, EPS, and net income growth raise concerns about future earnings sustainability. Overall, the company's strengths in profitability and solvency are tempered by weaknesses in liquidity and efficiency, requiring careful monitoring of operational performance to ensure long-term stability.
Gufic BioSciences Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation and efficient use of capital. Revenue and asset growth are also positive signs. However, liquidity is a concern, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios are low, which could point to issues with asset utilization. While the company maintains a good dividend coverage, declines in operating profit, EPS, and net income growth raise concerns about future earnings sustainability. Overall, the company's strengths in profitability and solvency are tempered by weaknesses in liquidity and efficiency, requiring careful monitoring of operational performance to ensure long-term stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
64.18
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
63.18
P/B RATIO
6.10
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
4.36
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
26.90
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹404.35 as on Aug 6, 2026.
The company's growth ratios present a mixed picture. Strong revenue and asset growth is offset by declines in operating profit, EPS, and net income growth. While the company is expanding its top-line and asset base, profitability is suffering. This suggests potential issues with cost management or pricing strategies. Maintaining revenue and asset growth while improving profitability will be critical for sustainable long-term performance.
| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | 1.61 | 15.12 | |
| Operating Profit Growth Rate | -9.33 | 11.03 | |
| Earnings Per Share (EPS) Growth | -19.09 | -7.91 | |
| Asset Growth Rate | 6.95 | 14.8 | |
| Net Income Growth Rate | -18.6 | -8.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 18 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 19 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 20 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
| 21 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral